AstraZeneca India s anti-diabetic drug receives approval for CKD treatment
AstraZeneca India s anti-diabetic drug receives approval for CKD treatment
08 February 2021 | News AstraZeneca’s dapagliflozin is the first medicine in SGLT-2i class to move into a new disease area by demonstrating efficacy and safety data for the treatment of patients with chronic kidney disease (CKD)
Source credit: Shutterstock
AstraZeneca India (AstraZeneca Pharma India Limited), a leading science-led biopharmaceutical company, announced that they have received marketing authorisation for their anti-diabetic drug dapagliflozin, in India for the treatment of patients of chronic kidney disease (CKD) up to Stage III. The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg into a new disease area to nephrologists in India.